Talphera Stock Price, News & Analysis
Company Description
Talphera, Inc. develops and seeks to commercialize specialty pharmaceutical therapies for use in medically supervised settings. The company’s disclosed business centers on product candidates used in controlled clinical or hospital environments, with its lead program focused on anticoagulation for extracorporeal blood circuits used during renal replacement therapy.
The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat. Talphera describes Niyad as an investigational anticoagulant for the extracorporeal circuit, and company materials state that it is being studied under an investigational device exemption. Niyad has received Breakthrough Device Designation from the U.S. Food and Drug Administration. The clinical program is tied to continuous renal replacement therapy, a critical-care setting involving extracorporeal blood filtration.
Talphera’s portfolio is described as including nafamostat product candidates and pre-filled syringe product candidates. Nafamostat candidates identified for the company include Niyad and LTX-608. The company’s operating model is based on advancing specialized therapeutic candidates through development, regulatory and clinical processes, and potential commercialization in medically supervised care settings.
Talphera is incorporated in Delaware and is headquartered in San Mateo, California. Its common stock trades on The Nasdaq Capital Market under the symbol TLPH. Public disclosures also show financings involving common stock and pre-funded warrants, equity incentive plans, stockholder voting matters, board governance and Nasdaq listing-compliance notices.
The company’s reporting history reflects a narrowed business focus following the divestment of DSUVIA, which Talphera has treated as a discontinued operation in its financial reporting. The current public-company profile is therefore centered on specialty pharmaceutical development, the Niyad program, clinical and regulatory activities related to medically supervised use, and the capital and governance matters associated with a small public life-sciences issuer.
Stock Performance
Talphera (TLPH) stock last traded at $0.7750, up 2.35% from the previous close. Over the past 12 months, the stock has gained 58.9%. At a market capitalization of $41.5M, TLPH is classified as a micro-cap stock with approximately 51.9M shares outstanding.
TLPH Rankings
Latest News
Talphera has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, conferences, management, private placement. View all TLPH news →
SEC Filings
Talphera has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G/A, 1 Form 4, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on May 21, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TLPH SEC filings →
Insider Radar
Insider buying activity at Talphera over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Talphera generated $28K in revenue over the trailing twelve months, operating income reached -$13.5M (-48157.1% operating margin), and net income was -$14.3M, reflecting a -51035.7% net profit margin. The company generated -$11.4M in operating cash flow. With a current ratio of 5.49, the balance sheet reflects a strong liquidity position.
Upcoming Events
Niyad PMA approval
PMA approval decision
Talphera has 2 upcoming scheduled events. The next event, "Niyad PMA approval", is scheduled for July 1, 2026 (in 23 days). Investors can track these dates to stay informed about potential catalysts that may affect the TLPH stock price.
Short Interest History
Short interest in Talphera (TLPH) currently stands at 1.0 million shares, down 15.3% from the previous reporting period, representing 2.9% of the float. Over the past 12 months, short interest has increased by 389.5%. This relatively low short interest suggests limited bearish sentiment. The 7.3 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Talphera (TLPH) currently stands at 7.3 days, down 16.3% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 8.7 days.
TLPH Company Profile & Sector Positioning
Talphera (TLPH) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing TLPH often look at related companies in the same sector, including Aytu Biopharma Inc (AYTU), Gelteq Limited (GELS), Flora Growth Corp (FLGC), Therapeuticsmd Inc (TXMD), and Incannex Healthcare Ltd (IXHL). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TLPH's relative position within its industry.